Reaction Details |
| Report a problem with these data |
Target | Bone morphogenetic protein receptor type-1B |
---|
Ligand | BDBM50262685 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_1349306 (CHEMBL3269164) |
---|
IC50 | 467±n/a nM |
---|
Citation | Jin, CH; Krishnaiah, M; Sreenu, D; Subrahmanyam, VB; Rao, KS; Lee, HJ; Park, SJ; Park, HJ; Lee, K; Sheen, YY; Kim, DK Discovery of N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline (EW-7197): a highly potent, selective, and orally bioavailable inhibitor of TGF-ß type I receptor kinase as cancer immunotherapeutic/antifibrotic agent. J Med Chem57:4213-38 (2014) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Bone morphogenetic protein receptor type-1B |
---|
Name: | Bone morphogenetic protein receptor type-1B |
Synonyms: | ALK-6 | ALK6 | BMPR1B | BMR1B_HUMAN | Bone morphogenetic protein receptor type-1B (BMPR1B) |
Type: | Enzyme |
Mol. Mass.: | 56939.41 |
Organism: | Homo sapiens (Human) |
Description: | O00238 |
Residue: | 502 |
Sequence: | MLLRSAGKLNVGTKKEDGESTAPTPRPKVLRCKCHHHCPEDSVNNICSTDGYCFTMIEED
DSGLPVVTSGCLGLEGSDFQCRDTPIPHQRRSIECCTERNECNKDLHPTLPPLKNRDFVD
GPIHHRALLISVTVCSLLLVLIILFCYFRYKRQETRPRYSIGLEQDETYIPPGESLRDLI
EQSQSSGSGSGLPLLVQRTIAKQIQMVKQIGKGRYGEVWMGKWRGEKVAVKVFFTTEEAS
WFRETEIYQTVLMRHENILGFIAADIKGTGSWTQLYLITDYHENGSLYDYLKSTTLDAKS
MLKLAYSSVSGLCHLHTEIFSTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVKFISD
TNEVDIPPNTRVGTKRYMPPEVLDESLNRNHFQSYIMADMYSFGLILWEVARRCVSGGIV
EEYQLPYHDLVPSDPSYEDMREIVCIKKLRPSFPNRWSSDECLRQMGKLMTECWAHNPAS
RLTALRVKKTLAKMSESQDIKL
|
|
|
BDBM50262685 |
---|
n/a |
---|
Name | BDBM50262685 |
Synonyms: | 6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine | 6-[4-(2-piperidin-1-ylethoxy)phenyl]-3-pyridin-4-ylpyrazolo[1,5-a]pyrimidine | CHEMBL478629 | Dorsomorphin | US9040694, Dorsomorphin |
Type | Small organic molecule |
Emp. Form. | C24H25N5O |
Mol. Mass. | 399.4882 |
SMILES | C(CN1CCCCC1)Oc1ccc(cc1)-c1cnc2c(cnn2c1)-c1ccncc1 |
Structure |
|